Mahshid Panahi , Fereshteh Rezagholizadeh , Shabnam Mollazadehghomi , Pooya Farhangnia , Mohammad Hadi Karbalaie Niya , Hossein Ajdarkosh , Fahimeh Safarnezhad Tameshkel , Seyed Mohammad Heshmati
{"title":"胰腺腺癌患者CD3+和CD8+肿瘤浸润淋巴细胞(til)与预后的关系","authors":"Mahshid Panahi , Fereshteh Rezagholizadeh , Shabnam Mollazadehghomi , Pooya Farhangnia , Mohammad Hadi Karbalaie Niya , Hossein Ajdarkosh , Fahimeh Safarnezhad Tameshkel , Seyed Mohammad Heshmati","doi":"10.1016/j.ctarc.2023.100699","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><strong>:</strong> Pancreatic adenocarcinoma (PDAC), with more than 250,000 deaths each year, is the eighth leading cause of death worldwide, with a five-year survival of less than 5% and a median recurrence time between 5 and 23 months. The association between PDAC and CD3<sup>+</sup>/CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs) and the extent of tumor spread and clinical outcomes has been recently shown. This study aimed to determine and compare the density of TILs and their association with disease prognosis in patients with PDAC.</p></div><div><h3>Materials and Methods</h3><p><strong>:</strong> In this study, we collected PDAC tissues and corresponding adjacent normal tissues from 64 patients with TIL-positive PDAC. The immunohistochemistry method was used for the detection of the expression levels of CD3<sup>+</sup> and CD8<sup>+</sup> TILs in PDAC tissues. Also, the completed follow-up history was evaluated for at least five years.</p></div><div><h3>Results</h3><p><strong>:</strong> The frequency of intratumoral and peritumoral TILs was 20 (31.2%) and 44 (68.8%), respectively. The mean density of CD3<sup>+</sup> TILs and CD8<sup>+</sup> TILs was 67.73%±20.17% and 69.45%±17.82%, respectively. The density of CD3<sup>+</sup> TILs and CD8<sup>+</sup> TILs was not associated with overall survival nor metastasis-free survival of the patients and tumor grade. However, the density of TILs was significantly lower in those patients who experienced tumor recurrence than those without this recurrence.</p></div><div><h3>Conclusion</h3><p><strong>:</strong> TILs density was high in patients with PDAC. The density of both CD3<sup>+</sup> and CD8<sup>+</sup> TILs was significantly lower in patients who experienced tumor recurrence. Thus, this study suggests that tracking and determining the density of CD3<sup>+</sup> and CD8<sup>+</sup> TILs might be effective in predicting PDAC recurrence.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"35 ","pages":"Article 100699"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma\",\"authors\":\"Mahshid Panahi , Fereshteh Rezagholizadeh , Shabnam Mollazadehghomi , Pooya Farhangnia , Mohammad Hadi Karbalaie Niya , Hossein Ajdarkosh , Fahimeh Safarnezhad Tameshkel , Seyed Mohammad Heshmati\",\"doi\":\"10.1016/j.ctarc.2023.100699\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><strong>:</strong> Pancreatic adenocarcinoma (PDAC), with more than 250,000 deaths each year, is the eighth leading cause of death worldwide, with a five-year survival of less than 5% and a median recurrence time between 5 and 23 months. The association between PDAC and CD3<sup>+</sup>/CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs) and the extent of tumor spread and clinical outcomes has been recently shown. This study aimed to determine and compare the density of TILs and their association with disease prognosis in patients with PDAC.</p></div><div><h3>Materials and Methods</h3><p><strong>:</strong> In this study, we collected PDAC tissues and corresponding adjacent normal tissues from 64 patients with TIL-positive PDAC. The immunohistochemistry method was used for the detection of the expression levels of CD3<sup>+</sup> and CD8<sup>+</sup> TILs in PDAC tissues. Also, the completed follow-up history was evaluated for at least five years.</p></div><div><h3>Results</h3><p><strong>:</strong> The frequency of intratumoral and peritumoral TILs was 20 (31.2%) and 44 (68.8%), respectively. The mean density of CD3<sup>+</sup> TILs and CD8<sup>+</sup> TILs was 67.73%±20.17% and 69.45%±17.82%, respectively. The density of CD3<sup>+</sup> TILs and CD8<sup>+</sup> TILs was not associated with overall survival nor metastasis-free survival of the patients and tumor grade. However, the density of TILs was significantly lower in those patients who experienced tumor recurrence than those without this recurrence.</p></div><div><h3>Conclusion</h3><p><strong>:</strong> TILs density was high in patients with PDAC. The density of both CD3<sup>+</sup> and CD8<sup>+</sup> TILs was significantly lower in patients who experienced tumor recurrence. Thus, this study suggests that tracking and determining the density of CD3<sup>+</sup> and CD8<sup>+</sup> TILs might be effective in predicting PDAC recurrence.</p></div>\",\"PeriodicalId\":9507,\"journal\":{\"name\":\"Cancer treatment and research communications\",\"volume\":\"35 \",\"pages\":\"Article 100699\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment and research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468294223000205\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000205","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma
Background
: Pancreatic adenocarcinoma (PDAC), with more than 250,000 deaths each year, is the eighth leading cause of death worldwide, with a five-year survival of less than 5% and a median recurrence time between 5 and 23 months. The association between PDAC and CD3+/CD8+ tumor-infiltrating lymphocytes (TILs) and the extent of tumor spread and clinical outcomes has been recently shown. This study aimed to determine and compare the density of TILs and their association with disease prognosis in patients with PDAC.
Materials and Methods
: In this study, we collected PDAC tissues and corresponding adjacent normal tissues from 64 patients with TIL-positive PDAC. The immunohistochemistry method was used for the detection of the expression levels of CD3+ and CD8+ TILs in PDAC tissues. Also, the completed follow-up history was evaluated for at least five years.
Results
: The frequency of intratumoral and peritumoral TILs was 20 (31.2%) and 44 (68.8%), respectively. The mean density of CD3+ TILs and CD8+ TILs was 67.73%±20.17% and 69.45%±17.82%, respectively. The density of CD3+ TILs and CD8+ TILs was not associated with overall survival nor metastasis-free survival of the patients and tumor grade. However, the density of TILs was significantly lower in those patients who experienced tumor recurrence than those without this recurrence.
Conclusion
: TILs density was high in patients with PDAC. The density of both CD3+ and CD8+ TILs was significantly lower in patients who experienced tumor recurrence. Thus, this study suggests that tracking and determining the density of CD3+ and CD8+ TILs might be effective in predicting PDAC recurrence.
期刊介绍:
Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.